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Introduction
Twenty-six years after the acquired immune deficiency syndrome 
(AIDS) was first reported, human immunodeficiency virus (HIV) 
infection still remains a major global challenge, especially in the 
southern part of sub-Saharan Africa. In South Africa, there were six 
million people infected, and more than 400 000 had died from AIDS 
by 2007.1-3
Currently, the most potent treatment for HIV infection is highly active 
antiretroviral therapy (HAART). This therapy is a combination of two 
or more antiretroviral drugs. These drugs work as inhibitors which 
contain five classes including entry inhibitors (EIs), nucleoside or 
nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleotide 
reverse transcriptase inhibitors (NNRTIs), integrase inhibitors (IIs) 
and HIV protease inhibitors (HPIs). This treatment can extend the 
lifespan of HIV-infected patients by suppressing HIV viral load, 
increasing CD4+ T-cella counts,b and reducing opportunistic infections 
associated with AIDS.4, 5
Unfortunately, besides improving patient prognosis, these drugs also 
result in metabolic abnormalities, in particular insulin resistance 
accompanied by dyslipidaemia,c hyperglycaemia and lipodystrophy.6,7 
Consequently, patients are also at high risk of developing premature 
cardiovascular morbidity and type 2 diabetes mellitus.8-11 
A substantial number of clinical and epidemiological studies have 
shown that HPIs play a major role in inducing metabolic disorders 
in HAART-treated patients.6,12,13 It appears that HPIs impair insulin-
mediated metabolism in adipose tissue and result in insulin 
resistance.14 However, the mechanisms for these side-effects are 
largely unknown. It is important to understand the mechanistic basis 
for these side-effects as the incidence of these is likely to increase 
as the rollout of antiretroviral drugs continues.
The insulin signalling pathway (see Figure 1)
Signalling through the insulin receptor pathway is critical for the 
regulation of blood glucose levels by insulin.15 In the post-prandial 
phase, in response to glucose, the pancreas releases insulin into the 
bloodstream. Insulin then binds to its receptor. The heterotetrameric 
(2 α- and 2 β-subunits) receptor is a ligand-activated tyrosine kinase. 
The binding of insulin leads to autophosphorylation of the receptor 
β-subunit on tyrosine residues. This then activates the intrinsic 
tyrosine kinase domain and leads to tyrosine phosphorylation 
of its substrate, insulin receptor substrate-1 (IRS-1). Typically, 
phosphotyrosine residues interact with a particular type of protein 
domain, Src homology 2 (SH2) domain with high specificity and 
affinity. The tyrosine phosphorylated IRS-1 binds to the SH2 domain 
of phosphoinositide 3-kinase (PI3-K) leading to activation of this 
enzyme and conversion of phosphatidylinositol 4,5-biphosphate 
(PIP
2) into phosphatidylinositol 3,4,5-triphosphate (PIP3). The bound 
PIP3 causes translocation of both PIP3-dependent protein kinase (PDK) 
and PKB, also known as Akt. This then allows PDK to phosphorylate 
and then activate (PKB). The activation of PKB/Akt is necessary for 
the final steps leading to glucose transport. This then results in the 
migration of glucose transporter 4 (GLUT4) from the cytoplasm to the 
cell membrane to facilitate the uptake of extracellular glucose. Some 
of the detailed final steps leading to the translocation of GLUT4 are 
still unclear and is still the subject of intensive research.
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a T cell or T helper cell is a subgroup of lymphocytes; a type of white cell which functions to activate other immune cells and express surface protein CD4
b This method is to detect HIV infection as HIV targets cells that express CD4+ T cells and reduces the circulating levels 
c Dyslipidaemia usually manifests as elevated triglycerides and cholesterol
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Insulin resistance and HIV protease inhibitors (HPIs)
The mechanism of insulin resistance induced by antiretroviral drugs 
is not well-understood. Insulin resistance occurs when normal 
insulin levels are inadequate to stimulate glucose uptake in the 
insulin signalling pathway in insulin-sensitive tissues such as liver, 
muscle and subcutaneous adipose tissue. The insulin resistance 
manifests as hyperinsulinaemia, hyperglycaemia and dyslipidaemia 
(hypertriglyceridaemia).
It has emerged that one class of the antiretroviral drugs, the HPIs, 
plays a critical role in inducing the side-effects. HPIs are potent 
competitive inhibitors of HIV aspartyl endopeptidase, an enzyme 
required for producing a mature HIV virion, such as saquinavir, 
indinavir, ritonavir, nelfinavir, amprenavir, lopinavir/ritonavir (Kaletra), 
fosamprenavir, atazanavir, tipranavir and darunavir.16
A clinical report revealed glucose intolerance and insulin resistance 
in HIV-positive patients treated with HPIs.17 Moreover, the incidence 
of insulin resistance in HIV-positive patients is significantly higher in 
HPI-treated patients than in patients treated with NRTIs or NNRTIs,18 
even when one considers related factors such as demography and 
virology.19 Furthermore, HPIs have been shown to induce insulin 
resistance in seronegative patients and in animal models,20-23 
implying a clear link between HPI use and insulin resistance. 
However, the underlying precise mechanisms have yet to be 
elucidated. The purpose of this review is to analyse the possible 
molecular mechanisms for the effects of the HPIs on the insulin 
signalling pathway.
HPIs impair the distal steps in the insulin signalling pathway
Initial studies examined the effects of antiretrovirals on both glucose 
transport and translocation of the intracellular glucose transporter, 
GLUT4. An early study of insulin resistance induced by HPIs 
demonstrated that the drug inhibits glucose uptake (measured by 
radioactive glucose uptake) without affecting GLUT4 translocation 
(assessed by immunostaining).24 GLUT4 is considered to be the 
major transporter responsible for insulin-stimulated glucose disposal 
into adipose tissue, cardiac and skeletal muscle, and plays a critical 
role in whole-body glucose homeostasis.25 In this particular study, 
it was reported that 3T3-L1 adipocytes treated with indinavir, an 
HPI, at 100 µM for 4 h displayed decreased glucose uptake. There 
was no evidence for any effects on early insulin signalling events 
such as insulin receptor and IRS-1 tyrosine phosphorylation or on 
the translocation of GLUT4 to the cell surface.24 In addition, indinavir 
did not have any effect on the activation of PKB/Akt. The effect of 
indinavir on glucose uptake was rapid and did not change even 
when indinavir was added 20 min after insulin stimulation indicating 
that the drug acted at a site distal to GLUT4 translocation.24 Similar 
effects on glucose uptake were reported in rats and in HIV-negative 
patients treated with HPIs.20,21,23 
However, in a subsequent study, it was reported that prolonged 
treatment (18 h) of 3T3-L1 adipocytes with nelfinavir, an HPI, at 
plasma concentrations (10 µM) impaired both GLUT4 translocation 
and glucose uptake.26 Nelfinavir appeared to induce insulin resistance 
by inhibiting the stimulation of PKB/Akt serine 473 phosphorylation 
without any effect on the tyrosine phosphorylation of IRS-1. Nelfinavir 
also decreased expression of the lipolysis regulator, perilipin.26 These 
effects of nelfinavir to impair PKB/Akt activation, GLUT4 translocation 
and glucose uptake were confirmed in a subsequent study. In this 
particular study, nelfinavir at 30 µM induced insulin resistance in 
3T3-L1 adipocytes by inhibiting recruitment and activation of PI3-K, 
leading to impaired GLUT4 translocation and thus preventing insulin-
stimulated glucose uptake.27,28 These effects were not accompanied 
by changes in insulin receptor expression or insulin receptor tyrosine 
phosphorylation.27 More recently, the effects of nelfinavir were 
studied in 3T3-L1 adipocytes expressing a GLUT4-green fluorescent 
protein (GFP) fusion protein to analyse transporter movement. Fusion 
of GLUT4 to GFP allows real time visualisation of glucose transporter 
movement under a fluorescent microscope. The authors of this study 
maintained that PKB/Akt activation was affected (i.e. inhibited) after 
insulin-stimulated generation of PIP3, leading to impaired GLUT4 
translocation because even when cellular levels of PIP3 were raised 
artificially by using a constitutively activated PI3-K, thus bypassing the 
requirement for normal insulin stimulation, nelfinavir inhibited GLUT4 
translocation.29 When a membrane targeted constitutively active PKB 
is expressed, in the presence of nelfinavir, PKB is phosphorylated 
normally by PDK and is able to induce GLUT4 translocation. The 
authors concluded that nelfinavir interfered with the “sensing” of 
PIP3 by PKB/Akt or the PIP3-induced translocation of PKB/Akt based 
on the fact that even in cells expressing a constitutively activated 
PI3-K, nelfinavir was still able to block the activation of PKB/Akt. 
IR = insulin receptor   
IRS-1 = insulin receptor substrate-1 
Y = tyrosine residue  
S = serine residue  
pY = phosphorylated tyrosine   
SH2 = Src homology 2 domain   
PTB = phosphotyrosine binding  
PH = Pleckstrin homology
PI3-K = phosphoinositide 3-kinase
PIP2 = phosphatidylinositol 4,5-biphosphate
PIP3 = phosphatidylinositol 3,4,5-triphosphate
PDK = PIP3-dependent protein kinase
PKB = protein kinase B
GLUT4 = glucose transporter 4
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Taken together, the results imply that nelfinavir has more profound 
effects on insulin signalling than indinavir. Indinavir inhibits glucose 
transport without affecting translocation, while nelfinavir inhibits 
both translocation and uptake, possibly at the level of PKB/Akt. 
The differences in the studies reviewed above may therefore have 
arisen from differences in the HPIs used or from the experimental 
methodology used to quantify GLUT4 translocation, which is often 
semi-quantitative and subjective, as compared to the measurement 
of glucose uptake.
The notion that nelfinavir has more profound effects is supported by 
studies on adipocytes that show that it induces oxidative stress.30 
Oxidative stress induces insulin resistance by activating serine 
kinases that lead to serine phosphorylation of IRS-1 and also by 
disrupting the subcellular distribution of PI3 kinase (i.e. decreased 
membrane localisation). This would in turn lead to decreased 
tyrosine phosphorylation of IRS-1 and consequently reduced PKB/
Akt activation and hence decreased GLUT4 translocation.
Do HPIs impair the proximal steps of the insulin signalling 
pathway?
The studies reviewed above suggest that the effects of HPI occur 
downstream in the insulin signalling pathway in 3T3-L1 adipocytes, 
in rats and humans,21,22,24 possibly at the level of PKB/Akt activation 
and beyond. However, there is evidence that HPIs possibly act at a 
more proximal level of the insulin signalling pathway. For example, 
in HepG2 hepatoma cells exposed to 100 µM indinavir for 48 h 
there was a 30–60% decrease in the insulin-stimulated tyrosine 
phosphorylation of IRS-1 and this was associated with decreased 
PI3-K activation and no change in insulin binding.31 In a subsequent 
study, it was found that ritonavir at 10 µM decreased insulin 
receptor numbers in 3T3-L1 pre-adipocytes without any effect on 
binding affinity. This was accompanied by decreased IRS-1 tyrosine 
phosphorylation in response to insulin. 32 
A more recent study suggested that lopinavir, an HPI, inhibited IRS-1 
phosphorylation in human adipocytes and resulted in a concentration-
dependent decrease in glucose uptake.33 It was proposed that 
the drug decreased the phosphorylation of IRS-1 directly since 
there was no effect observed on the phosphorylation of the insulin 
receptor β-subunit i.e. the decrease in IRS-1 phosphorylation was 
primary, rather than secondary to a change in receptor activation. 
Taken together, these data imply that some of the HPIs may impair 
the earlier steps in the insulin signalling pathway.
The differences in the studies reviewed above are likely to be due 
to differences in experimental design, cell types, types of HPIs used 
and durations of exposure. It is possible that, differences between 
the various drugs on protein and gene expression in cells are more 
likely to be unmasked after prolonged exposure, hence resulting in 
different final observations in the various studies. These differences 
will be exaggerated further when different cell lines are used. Overall, 
however, it appears that the final common pathway is an effect on 
glucose transport and that all of the HPIs reviewed above display 
some effect at one or more steps in the insulin signalling pathway.
Other factors involved in the insulin resistance induced by 
HPIs: oxidative stress, adapter proteins and adipokines
As mentioned above, some of the HPIs may increase oxidative 
stress.30,34 HPIs may also alter chemokines, cytokines or adiponectin 
production in human adipocytes and macrophages.35 The induction 
of oxidative stress is known to cause insulin resistance. 
Changes in the expression of regulatory proteins could also potentially 
explain the effects of HPIs. Suppressor of cytokine signalling-1 
(SOCS-1) is one example of a known inducer of insulin resistance. 
SOCS-1 and the related protein suppressor of cytokine signalling-3 
(SOCS-3) bind to the insulin receptor following activation and impair 
the ability of the insulin receptor to phosphorylate downstream 
substrates. In addition, SOCS proteins are able to target IRS-1 for 
degradation. In essence, increased expression of SOCS proteins will 
interfere with the signalling functions of the insulin receptor and IRS-
1. In addition to the previously described effects on the signalling 
proteins in the early part of the insulin signalling pathway, it has also 
been shown that the expression of SOCS-1 was increased in rats 
exposed to indinavir for seven weeks.36 In this study, chronic HPI 
exposure induced SOCS-1 expression in muscle, liver and adipose 
tissue. This was associated with an increase in the expression of 
tumour necrosis factor-α (TNF-α) and the downstream target 
sterol regulatory element-binding protein-1 (SREBP-1) along with 
decreased expression of insulin receptor substrate-2 (IRS-2). IRS-2 
is another major substrate that mediates insulin action in the insulin 
signalling pathway. 
TNF-α induces insulin resistance primarily by affecting the function 
of IRS proteins. It can also induce the expression of SOCS-1. As 
discussed above, the association of increased TNF-α in animals 
exposed to indinavir may have arisen from the induction by TNF-α 
or by another unknown mechanism. 
In relation to IRS-1, TNF-α induces the activation of several serine 
kinases (c-Jun N-terminal kinase (JNK); inhibitor κB kinase (IKK)) 
leading to increased serine phosphorylation of IRS-1. Increased 
serine phosphorylation of IRS-1 converts it into an inhibitory protein 
of the insulin receptor, leading to insulin resistance. Therefore, in 
summary, TNF-α can induce insulin resistance by affecting IRS-1 
function directly or by inducing the expression of SOCS-1.
HPIs have also been found to alter adipose tissue gene expression in 
vivo.37 The mRNA expression levels of the CCAAT/enhancer-binding 
protein α, leptin, and adiponectin in HIV-positive patients treated 
with HPIs have been found to be significantly lower than in HPI-naive 
patients.37 Since adiponectin levels are important in the whole body 
response to insulin, a lowering of adiponectin would affect glucose 
homeostasis adversely and oppose the actions of insulin.
Summary (see Table I)
The individual differences in the effects of HPIs observed in 
the different studies may be attributed to the different HPI drugs 
used in the studies and in experimental design. HPIs induce 
different effects on different cell lines.38,39 Additionally, several 
HPIs demonstrate different results in vitro and in vivo.40 The most 
consistent phenomenon observed has been the effect on glucose 
uptake, the most obvious physiological end result of insulin. Whether 
these phenomena arise primarily from effects on early steps in the 
insulin signalling pathway is not entirely clear. Recent studies29,33 
support the idea that HPIs affect a more proximal level of the 
insulin signalling pathway, in particular tyrosine phosphorylation of 
the insulin receptor and its substrate, IRS-1. This then leads to the 
secondary inhibition of downstream events in the insulin signalling 
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cascade, in particular, extracellular glucose uptake by GLUT4. With 
the exception of the studies cited, there is a paucity of studies that 
have examined the proximal steps in the insulin receptor signalling 
cascade, particularly at the early steps in the activation of the insulin 
receptor tyrosine kinase.
Conclusion
Insulin resistance is a major complication of treatment with 
antiretroviral drugs. With the increased longevity of patients following 
antiretroviral treatment, the incidence of these complications is 
likely to increase. An understanding of the molecular basis of these 
complications could lead to the development of diagnostic tests to 
predict the onset of the side-effects or alternatively to rational drug 
design. In conclusion, the studies reviewed above suggest that the 
manifestation of insulin resistance due to HPI treatment is likely to be 
associated with dysregulation of several cellular factors, specifically 
in the early steps in the pathway of insulin receptor signalling, in 
addition to alterations in GLUT4 transporter function. Alternatively, 
the perturbation of glucose transport may be secondary to inhibition 
of critical steps early in the signalling pathway.
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Table I: Summary of the effect of HPIs in the insulin signalling pathway
HPI Effects References Drug Experimental model Observations
1)  The distal steps in the 
insulin signalling pathway
Murata et al (2000)24 Indinavir (100 µM) for 4 h 3T3-L1 adipocytes Decreased glucose uptake
Rudich et al (2001)26 Nelfinavir (10 µM) for 18 h 3T3-L1 adipocytes Impaired GLUT4 translocation and glucose uptake 
by inhibiting stimulation of PKB serine 473 phos-
phorylation
Ben-Romano et al (2004)27 
and Rudich et al (2005)28
Nelfinavir (30 µM) for 18 h 3T3-L1 adipocytes Inhibited recruitment and activation of PI3-K, 
impaired GLUT4 translocation and glucose uptake
Kachko et al (2009)29 Nelfinavir (30 µM) for 18 h 3T3-L1 adipocytes used 
a GLUT4-GFP chimeric 
construct
Interfered with the sensing of PIP3 by PKB/Akt and 
inhibited GLUT4 translocation
2)  The proximal steps in the 
insulin signalling pathway
Schutt et al (2000)31 Indinavir (100 µM) for 48 h HepG2 hepatoma cells Decreased tyrosine phosphorylation of IRS-1 and 
PI3-K activation
Cammalleri and Germinario 
(2003)32
Ritonavir (10 µM) for 11 days 3T3-L1 pre-adipocytes Decreased insulin receptor expression and tyrosine 
phosphorylation of IRS-1
Djedaini et al (2009)33 Lopinavir (10 µg/ml) for 48 h Human adipocytes Decreased tyrosine phosphorylation of IRS-1 and 
glucose uptake
3)  Other factors Ben-Romano et al (2006)30 Nelfinavir (30 µM) for 18 h 3T3-L1 adipocytes Induced oxidative stress
Lagathu et al (2007)35 Indinavir, amprenavir, lopinavir, ritonavir 
(10 µmol/l), atazanavir (4 µmol/l),  
nelfinavir (5 µmol/l) for 24 and 48 h
Human adipocytes and 
macrophages
Induced oxidative stress and altered chemokines, 
cytokines or adiponectin production
Carper et al (2008)36 Indinavir (20 µM) for 7 weeks Rats Increased SOCS-1, TNF-α and SREBP-1 expression
Chapparo et al (2005)37 Indinavir, nelfinavir, liponavir/ritonavir, 
ritonavir and saquinavir
Human adipose tissue 
biopsies
Altered adipose tissue gene expression
